{"url_path":"/sec/pyxs/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1782223/0001193125-26-222843-index.html","accession_number":"0001193125-26-222843","cik":"0001782223","ticker":"PYXS","issuer_name":"Pyxis Oncology, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1782223/0001193125-26-222843-index.html","primary_entity_key":"0001782223","primary_entity_name":"Pyxis Oncology, Inc."},"word_count":128,"has_tables":true,"body_markdown":"Item 5. Other Information.\n\nTrading arrangement\n\nDuring the quarter ended March 31, 2026, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of Regulation S-K for the purchase or sale of our securities, except as set forth below:\n\nName and Title\n\nType of Plan\n\nAdoption or Termination Date\n\nPlan Start Date\n\nPlan End Date\n\nAggregate Number of Securities to be Sold\n\nDescription of Trading Arrangement\n\nJitendra Wadhane, Principal Financial and Accounting Officer\n\nRule 10b5-1 trading arrangement\n\nAdopted on March 25, 2026\n\nMarch 25, 2026\n\nDecember 15, 2026\n\n98,148\n\nSales of shares intended to satisfy the affirmative defense of Rule 10b5–1(c)\n\n \n\n \n\n66"}